ClinicalTrials.gg
CompletedNCT06781619PRO-PLANTUpdated Oct 8, 2026

Effect of Plant Based High Energy High Protein Oral Nutritional Supplement on Nutritional Intake in Patients With or at Risk of Disease Related Malnutrition.

An interventional study of Test Product: Plant based high energy high protein ONS and Control Product: Dairy based high energy high protein ONS in Disease Related Malnutrition, sponsored by Nutricia Research. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Nutricia Research (part of Danone) · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 8, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Malnutrition by Danone — 2 open to participants now, 3 under way, none of them phase 3. Malnutrition · Danone.

Enrollment
5th of 11
76 · median 73
Started
2025
the only one that year
No phase
9 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Malnutrition by Danone, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 12th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

2 of the 12 studies in Malnutrition by Danone are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Malnutrition by Danone, or all of them as a file.
02

Study summary

The subjects will use study product twice daily for 8 weeks starting at Visit 1. The recommendation is to consume one serving in the morning and one in the afternoon / evening between meals. The duration of the study for each subject will be approximately 11 weeks, comprising a screening period of max 2 weeks, an intervention period of 8 weeks, and a follow up phone call 1 week after completion of the intervention. A blood sample will be drawn at visit 1 and visit 3.

03

Conditions studied

  • Disease Related Malnutrition

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Identified as at medium or high risk of malnutrition based on:

    1. MUST score ≥ 1 and / or
    2. Being prescribed with ONS and willing and able to switch from pre-study prescribed ONS to the Test or Control Product for participation in the study
  3. In need of 2 servings of ONS/day (400 kcal; 20 gr protein per serving) for at least 8 weeks as determined by the treating healthcare professional.
  4. Medically and physically able to consume high energy high protein ONS in the opinion of the Investigator.
  5. Willing to maintain dietary habits for the duration of the study.
  6. Willing to consume plant based as well as dairy based ONS

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to soy, cow's milk protein or to any other ingredients as listed in the study product composition (refer to the product information brochure (PIB) and the appendix of this protocol).
  2. Known intolerance to any ingredients as listed in the study product composition (refer to PIB and appendix of this protocol). Subjects with lactose intolerance who use lactase may still be enrolled in the study.
  3. Any to oral feeding per se, including gastrointestinal failure or suppressed gastrointestinal function, complete intestinal obstruction and major intraabdominal sepsis.
  4. Active flare of inflammatory bowel disease as defined by Harvey-Bradshaw Index (HBI) >6 (Crohn's disease) or Simple Clinical Colitis Activity Index (SCCAI) >5 (ulcerative colitis).
  5. Requiring a protein restricted diet as confirmed by a physician, for example chronic kidney disease stage 4 and 5 (estimated by \<30 mL/min/1.73 m2).
  6. Requiring enteral nutrition (via tube delivery) or parenteral nutrition.
  7. Subjects following a vegan diet.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Plant Based High Energy High Protein (PB HEHP) Oral Nutrition Supplement (ONS)

    Test Product

    Dietary Supplement: Test Product: Plant based high energy high protein ONS

  • Active comparator
    Diary Based High Energy High Protein (DB HEHP) Oral Nutrition Supplement (ONS)

    Control Product

    Dietary Supplement: Control Product: Dairy based high energy high protein ONS

Interventions

  • Dietary supplementTest Product: Plant based high energy high protein ONS

    Plant based high energy high protein ONS 2 servings/day for a period of 8 weeks.

  • Dietary supplementControl Product: Dairy based high energy high protein ONS

    Dairy based high energy high protein ONS 2 servings equivalent in energy \& protein for a period of 8 weeks.

06

What researchers measure

Primary outcomes

  1. To investigate the effect of PB HEHP ONS compared to DB HEHP ONS on nutritional intake (energy & protein) in subjects with or at risk of Disease Related Malnutrition (DRM) and/or prescribed with ONS.

    Mean total protein intake and mean total energy intake in subject with or at risk of Disease Related malnutrition (DRM) and/or prescribed with ONS will be measured by 3-day nutritional intake diary at baseline, at week 4 and week 8.

    Time frame: 11 weeks

07

Study locations

2 sites
  • Meclinas
    Mechelen, 2800, Belgium
  • QClinical
    Rotterdam, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Sep 2026, 17 months.

Of 419 interventional studies with no phase under Malnutrition, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 17 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Sep 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 17, 2025
StartActual
Mar 17, 2025
Primary completionActual
Sep 8, 2026
CompletionActual
Sep 8, 2026was Jul 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 8, 2026
Study completion
Jul 2027→Sep 8, 2026 (actual)
Oct 8, 2026
Enrollment
80 (estimated)→76 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Completed
    Study completion Jul 2027→Sep 8, 2026 (now actual)
    Enrollment 80 (estimated)→76 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06781619
Lead sponsor
Nutricia Research
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Mar 17, 2025
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion